瑞士制药商诺华（Novartis，美股代码：NVS）与药物研发公司蒙特罗萨治疗公司（Monte Rosa Therapeutics，股票代码：GLUE）于周一签署一项价值高达 57 亿美元的授权协议，共同研发免疫介导性疾病治疗药物。

　　根据协议，蒙特罗萨治疗公司将获得 1.2 亿美元预付款；若达到相关里程碑目标，且未来药物实现销售，该公司还将获得里程碑付款及销售提成，总金额最高可达 57 亿美元。

　　这是诺华本月达成的第二项重大合作协议。此前，该公司刚与中国阿戈生物制药公司（Argo Biopharmaceutical）签署一项价值高达 52 亿美元的协议，共同开发实验性心脏疾病治疗药物。

　　消息公布后，蒙特罗萨治疗公司的股价在盘前交易中暴涨 50%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：郭明煜

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.